A single synthetic peptide, injected into mice, raised antibodies that recognized human, swine, and avian influenza at once, including the H5N1 bird flu that pandemic planners watch most closely.
The peptide is called LHNVD-110, and the work appeared in the July issue of Influenza and Other Respiratory Viruses ↗. It comes from Longhorn Vaccines and Diagnostics, a Gaithersburg, Maryland company that has spent years arguing a flu vaccine does not need to be rebuilt every season. The team immunized outbred mice, animals bred to be genetically varied rather than a uniform lab strain, which makes their response a little more like a real population's. Then they measured what those immune systems made.
What the peptide is
Most flu vaccines carry whole viral proteins, usually hemagglutinin, the surface protein the virus uses to enter cells. Those proteins mutate fast, which is why the shot is reformulated annually and why it can miss when the circulating strain drifts. LHNVD-110 takes a different route. It is a single, unconjugated peptide (a short string of amino acids, not stitched onto a carrier protein) that strings together several small fragments the flu virus cannot easily change. Those fragments are drawn from three viral parts at once: hemagglutinin, neuraminidase (the second surface protein, the target of drugs like Tamiflu), and the internal matrix proteins that are nearly identical across flu subtypes.
The bet is that by aiming antibodies at the conserved scaffolding rather than the fast-moving surface, one peptide can cover strains that normally need separate vaccines.
What the mice made
The immunized mice produced both arms of the antibody response in balance. They raised IgG1 antibodies, which sit on the side of the immune system tuned for antibody output, and IgG2a antibodies, which sit on the side tuned for infected-cell killing. A vaccine that pushes only one arm tends to protect narrowly; a balanced response is what developers want from a candidate meant to cover many strains.
More to the point, the antibodies were cross-reactive. The team checked this with hemagglutination inhibition and microneutralization assays, two standard tests of whether serum can actually block a virus. The mouse antibodies inhibited 2009 pandemic H1N1, seasonal H3N2, the highly pathogenic H5N1 avian strain, and an influenza B Victoria-lineage virus. Those four cover the human seasonal viruses, the swine-origin pandemic lineage, and the bird flu that has been moving through poultry and dairy cattle.
The paper reports these results in qualitative terms in its abstract, and the strain-by-strain titers sit in the full text. The honest read is that this is an immunogenicity study, not a challenge or efficacy study. It shows the vaccine raises the right kind of broad antibody in an animal. It does not yet show that a vaccinated animal survives infection, and mice are not people.
Why it is worth tracking
Longhorn has presented LHNVD-110 data at vaccine meetings and has tested the single-peptide approach in pigs, animals whose flu biology is closer to ours and which the company describes as a more demanding model ↗. The pitch the company keeps making is manufacturing: a chemically synthesized peptide is cheaper and faster to make at scale than an egg-grown or cell-grown protein vaccine, which matters if the goal is a stockpile-ready shot for the next pandemic rather than a seasonal product.
That is the part to weigh against the data. A universal flu vaccine has been promised for two decades and none has reached the clinic, usually because broad immunogenicity in mice has not translated into durable protection in humans. LHNVD-110 clears the first bar this paper set for it. The bars that decide whether it matters, human trials and a real H5N1 challenge, are still ahead.
The candidate is a peptide vaccine, the class of immune-directed peptides ↗ that peptidemodel tracks alongside the metabolic and oncology molecules that dominate the pipeline. It does not yet have a card on the platform.